GlassScriptPhysician profile
Lileta Wint
NPI 1649690942
$10,455.05
in general payments reported to CMS, 2019-2025
46 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,950 · 2022: $2,654 · 2023: $2,234 · 2024: $2,183 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,851.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,509.16 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,732.10 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Ironwood Pharmaceuticals, INC | $723.12 | 2021-2024 | Linzess |
| Daiichi Sankyo INC. | $625.94 | 2021-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $565.40 | 2022-2025 | |
| Pfizer INC. | $555.78 | 2021-2025 | |
| Lilly USA, LLC | $523.45 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $369.99 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $242.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $224.42 | 2021-2025 | Onpattro |
| Ardelyx, INC. | $216.69 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $182.30 | 2021-2023 | Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.28 | 2021-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $138.25 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $138.16 | 2021-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lileta Wint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.